In a public health center in South Korea, a patient's joint range of motion is no longer measured with a goniometer and a clipboard. Instead, a camera system tracks their movement in three dimensions, feeding data into an AI that coaches their exercise form in real time. This is the quiet, institutional deployment of MyBeneFit's Virtual Mate, a system that has found its first market not in consumer apps, but in the government-funded gyms where health is a public service.
For five consecutive years, the Seoul-based startup has been selected for a central-government project managing the physical fitness of civil servants [DBR, October 2026]. That recurring contract, alongside deployments in public health and welfare centers nationwide, forms the core of a bet that standardized, data-driven assessment can be the foundation for more serious digital health interventions. The company is now collecting that assessment data, including posture and joint mobility, to build what it calls personal fitness records, with an eye on conditions like sarcopenia and prediabetes [MyBeneFit company news, May 2025].
The Institutional Wedge
MyBeneFit's path is distinct from the flashier world of consumer fitness apps. Its flagship product, Virtual Mate, is a B2B2C play, installed in centers where trainers use a companion app to register members. The consumer-facing myBenefit app then allows those users to access AI-based exercise programs, but only after that institutional gate [Google Play, Unknown]. This model provides a controlled environment for data collection and a built-in distribution channel through public procurement.
The technology itself hinges on 3D motion-recognition to analyze movement and provide real-time AI coaching [DBR, October 2026]. While similar computer vision tech exists in premium home fitness equipment, MyBeneFit's focus on the public sector addresses a different need: scalable, objective assessment for population health. The data voucher project it won in 2024 aimed to standardize a health-exercise model using this lifecycle assessment data [MyBeneFit company news, May 2025].
Funding and Strategic Alignment
The company's most recent validation came in October 2026, with a KRW 3 billion Series A round that brought its cumulative funding to approximately KRW 7 billion (about $5.1 million) [DBR, October 2026]. The lead investor was not a traditional venture fund but InBody, the manufacturer of medical-grade body composition analyzers. This strategic partnership suggests a vision where InBody's biometric data and MyBeneFit's movement data could eventually combine for a more holistic health profile.
Pre-Series A (Aug 2025) | 4 | B KRW Cumulative
Series A (Oct 2026) | 7 | B KRW Cumulative
The investor syndicate reveals a focus on sports, biotech, and regional development funds, including NH Investment & Securities and the Sports Innovation Investment Association [MoneyToday, October 2026]. This backing underscores the company's hybrid identity, sitting at the intersection of fitness, healthcare, and public infrastructure.
The Team and Traction
MyBeneFit is led by co-CEOs Jeong Seok-mo and Kwon Hee-jin [DBR, October 2026]. Public records show an unconventional background for co-founder Jeong, who is also known as Jeong Seok-won, a musician, composer, and actor with credits in South Korean film and television [IMDb, retrieved 2026]. This profile is far from the typical clinical or AI research founder, suggesting the operational and creative helm may lie with Kwon or an unlisted team. The company claims over 15 years of prior experience from a fitness center management company, which would provide essential domain knowledge for the institutional sales motion [Tradekorea, Unknown].
Traction is defined by public sector adoption. The five-year civil servant project is the flagship reference, proving the company's ability to navigate government procurement and deliver a standardized service at scale. Nationwide deployment in public health centers represents a significant, if diffuse, installed base that provides a steady stream of assessment data.
The Data Ambition and Its Hurdles
The company's stated goal moves beyond fitness assessment into digital therapeutics. It is developing data applications focused on specific, challenging chronic conditions: sarcopenia (age-related muscle loss), mild cognitive impairment, prediabetes, and supporting cancer survivors [MyBeneFit company news, May 2025]. This is where the bet gets ambitious, and where Pulse Raman's lens turns to the regulatory and clinical pathway.
For a digital tool to be used in managing these conditions, especially within a public health system, the evidence bar is high. The leap from a 3D motion coach to a clinically validated intervention for sarcopenia is substantial. It requires peer-reviewed studies, likely clearance from regulators like South Korea's Ministry of Food and Drug Safety (MFDS), and integration into clinical care pathways. MyBeneFit has not yet published data or announced regulatory submissions for these intended uses.
The risks here are not about the technology's basic function, but about its evolution into a medical tool.
- Clinical validation. Motion data correlates with function, but proving it can reliably diagnose or manage a specific disease requires rigorous trials.
- Regulatory classification. As software intended to treat or manage a disease, it may be classified as a medical device, triggering a new layer of compliance.
- Go-to-market shift. Selling to public gyms is different from selling to hospitals or prescribing physicians, requiring new sales muscle and proof of cost-effectiveness.
The company's most plausible answer is patience. Its public-sector deployments provide a live dataset to refine its algorithms. The partnership with InBody offers a channel to more clinical settings. The next logical step would be a pilot study, conducted with a research hospital, to begin generating the evidence needed for the broader ambition.
The Standard of Care Today
For the patient populations MyBeneFit is ultimately targeting, the current standard of care is often fragmented and subjective. An older adult with suspected sarcopenia might undergo a slow, manual assessment like a grip strength test or a gait speed measurement in a clinic, with limited follow-up. A cancer survivor rehabilitating after treatment may receive generic exercise pamphlets. The promise of a tool like Virtual Mate is continuous, objective measurement in a community setting, creating a digital record that could help flag decline earlier or personalize rehab protocols.
The next twelve months for MyBeneFit will likely focus on leveraging the InBody partnership and deepening its government engagements. The key milestone to watch will be any announcement of a formal clinical research partnership or a regulatory filing for one of its target conditions. That would signal the company is beginning the long, hard, but necessary work of turning a clever fitness assistant into a validated health intervention.
Sources
- [DBR, October 2026] MyBeneFit Raises KRW 3 Billion Series A; InBody Joins as Strategic Investor | https://dbr.donga.com/kfocus/view/donga/article_no/3763
- [MoneyToday, October 2026] 마이베네핏, 시리즈A 30억 투자 유치… 인바디 전략적 투자자 합류 | https://www.mt.co.kr/future/2026/10/19/2026101916362951981
- [MyBeneFit company news, May 2025] 2024년 데이터바우처 지원사업… | https://www.mybenefit.co.kr/bbs/?so_table=news&mode=VIEW&num=59&category=&findType=&findWord=&sort1=&sort2=&page=1
- [MyBeneFit company news, August 2025] 마이베네핏, 누적 투자 40억 달성… 기술력·공공성 입증 디지털 헬스… | https://www.mybenefit.co.kr/bbs/?so_table=news&mode=VIEW&num=63&category=&findType=&findWord=&sort1=&sort2=&page=1
- [Google Play, Unknown] myBenefit(마이베네핏) - Apps on Google Play | https://play.google.com/store/apps/details?id=com.benefit.virtualmate.member&hl=en_US&gl=US
- [IMDb, retrieved 2026] Jeong Seok-won | https://www.imdb.com/name/nm3756197/
- [Tradekorea, Unknown] Tradekorea | https://mybenefit.tradekorea.com/company.do